We next sought to determine whether activating PPARα may rescue the pro-hypertrophic effects of Fabp3 defect after TAC operation and search for clinical benefits on the treatment of cardiac hypertrophy. This evidence concerns the gene FABP3 and cardiac hypertrophy.